Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold by Baillache, Daniel J. & Unciti-broceta, Asier
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent developments in anticancer kinase inhibitors based on
the pyrazolo[3,4-d]pyrimidine scaffold
Citation for published version:
Baillache, DJ & Unciti-broceta, A 2020, 'Recent developments in anticancer kinase inhibitors based on the
pyrazolo[3,4-d]pyrimidine scaffold', RSC Medicinal Chemistry. https://doi.org/10.1039/D0MD00227E
Digital Object Identifier (DOI):
10.1039/D0MD00227E
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
RSC Medicinal Chemistry
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 06. Nov. 2020
RSC
Medicinal Chemistry
REVIEW
Cite this: DOI: 10.1039/d0md00227e
Received 3rd July 2020,
Accepted 1st September 2020
DOI: 10.1039/d0md00227e
rsc.li/medchem
Recent developments in anticancer kinase
inhibitors based on the pyrazolo[3,4-d]pyrimidine
scaffold
Daniel J. Baillache and Asier Unciti-Broceta *
Pyrazolo[3,4-d]pyrimidines have become of significant interest for the medicinal chemistry community as a
privileged scaffold for the development of kinase inhibitors to treat a range of diseases, including cancer.
This fused nitrogen-containing heterocycle is an isostere of the adenine ring of ATP, allowing the
molecules to mimic hinge region binding interactions in kinase active sites. Similarities in kinase ATP sites
can be exploited to direct the activity and selectivity of pyrazolo[3,4-d]pyrimidines to multiple oncogenic
targets through focussed chemical modification. As a result, pharma and academic efforts have succeeded
in progressing several pyrazolo[3,4-d]pyrimidines to clinical trials, including the BTK inhibitor ibrutinib,
which has been approved for the treatment of several B-cell cancers. In this review, we examine the
pyrazolo[3,4-d]pyrimidines currently in clinical trials for oncology patients, as well as those published in the
literature during the last 5 years for different anticancer indications.
Introduction
Cancer is amongst the leading causes of death worldwide,
accounting for approximately 10 million deaths each year.1,2
While some cancers are treatable and patients can benefit
from high survival rates, several cancers have significantly
lower survival rates, representing a significant unmet clinical
need. Cancers characterised by high mortality that require
more effective treatments include lung, brain, oesophageal
and pancreatic cancers.3 The development of new treatments
is challenging as cancer is a complex and heterogeneous
disease, characterised by multiple mutational profiles
underpinning its numerous common hallmarks.4 Self-
stimulated proliferation, resistance to programmed cell
death, limitless replicative potential and high levels of
invasion are all common traits of cancer that can result from
the overactivation of oncogenic pathways and/or the
deactivation of tumour suppressor mechanisms.5
Protein kinases are enzymes responsible for the transfer
of a phosphate group from ATP to a substrate. 518 different
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protein kinase genes have been identified to date.6 Based on
the kinase substructure and the residues which they
phosphorylate, the kinases can be further grouped into
families and sub-families.6 Kinases play a critical role in
many different cellular processes essential in the
development and progression of disease, including cancer,
inflammation, fibrosis, and neurological diseases.6,7 In
cancer, mutations in kinases can trigger oncogenesis and are
key contributors to cancer progression.8 As a result, kinase
inhibitors have become a highly important class of
oncodrugs in the last two decades.
Following the approval of the first kinase inhibitor in
2001, imatinib (Gleevec), a BCR-ABL inhibitor used to treat
chronic myeloid leukaemia and acute lymphocytic leukaemia,
over 50 kinase inhibitors have been approved for a variety of
indications, from cancer to fibrosis and inflammation,
amongst others.9,10 More than 45 of these inhibitors have
been approved for the treatment of cancer, a number that
grows quickly every year.9 Further to the approved inhibitors,
over 200 small molecule kinase inhibitors are currently in
clinical trials for many indications, though this figure is
likely to be far higher.11 All but two approved inhibitors are
administered orally, indicating that this class of inhibitors
share structural characteristics and physicochemical
properties.9 Most kinase inhibitors prevent the
phosphorylation process, primarily through competition with
the phosphate-donating ATP or the kinase substrate. Several
studies have examined the possible binding modes for
kinases inhibitors, with multiple modes being defined based
upon how the inhibitor and kinase interact with eachother.9
Among the variety of privileged heterocycles explored in
the design of small molecule drugs, pyrazolopyrimidines are
one of the most versatile.12,13 Comprised of a fused pyrazolo
ring and pyrimidine ring, this scaffold is a bioisostere of
adenine and can mimic key interactions of ATP with the
hinge region of the kinase domain.13,14 This family of
molecules can be further subdivided in various isomeric
forms based on the configuration of the nitrogen atoms
around the heterocycle. One of the most employed ones in
drug discovery is the pyrazolo[3,4-d]pyrimidine bicycle, which
has been shown to possess great potential as the basis of
pharmacological agents for a range of indications, including
antivirals, antimicrobials, antitumor agents, pesticides, CNS-
agents, etc.13 To the best of our knowledge, the first
pyrazolo[3,4-d]pyrimidine kinase inhibitors identified were
PP1 (1) and PP2 (2), which were first discovered to act as
kinase inhibitors of the SRC family of non-receptor tyrosine
kinases in 1996 (Fig. 1).15 Years later, in 2013, ibrutinib
(Imbruvica), 3 (Fig. 2), was approved by the FDA for the
treatment of B-cell cancers.16 The discovery of 3 was unique
for two reasons; firstly it was the first example of an
irreversible kinase inhibitor to be approved, as the α,β-
unsaturated carbonyl moiety is able to undergo a Michael
addition with the thiol of cysteine residues in its target
kinase BTK.17,18 Secondly it was the first kinase inhibitor to
be approved possessing a pyrazolo[3,4-d]pyrimidine core. 3 is
a potent and selective inhibitor of B-cell activation. B-Cells
play important roles in the body's immune system, regulating
immune responses by producing antibodies and using their
surface receptors to bind to and trigger specific responses
against antigens. BTK is a key component of the B-cell
antigen receptor (BCR) signalling pathway.16,18 Disruption in
B-cell activities can result in autoimmune diseases such as
arthritis, and mutations in B-cells and their precursors can
cause a range of cancers, such as leukaemia and
lymphoma.18 3 was originally approved for chronic
lymphocytic leukaemia (CLL), and later for mantle cell
lymphoma (MCL) and Waldenström macroglobulinemia, with
approvals for other lymphomas following. Since then, it has
entered clinical trials for other indications, such as
glioblastoma, breast, lung and pancreatic cancers,19,20 and it
was approved for the treatment of graft vs. host disease in
2017.
Pyrazolo[3,4-d]pyrimidines in clinical
trials
While only 3 has so far been approved as a pyrazolo[3,4-d]
pyrimidine containing kinase inhibitor, at present, a further
three molecules are in clinical trials; parsaclisib, sapanisertib
and umbralisib.11
Sapanisertib (otherwise known as INK128 or MLN1028, 4,
Fig. 2) is an experimental kinase inhibitor, currently in
clinical trials for several cancer indications.20,21 4 is an
example of a mTOR inhibitor, inhibiting both the mTORC1
and 2 complexes. Mutations in mTOR signalling pathways
are present in cancer cell growth and development. Prior to
the development of mTOR inhibitors such as 4, only rapalogs
were known to inhibit the mTOR pathway by selectively
inhibiting mTORC1, which results in a reduction of their
anticancer efficacy due to compensatory activation of the
mTORC2 complex. Dual mTORC1/2 inhibitors are proposed
to be more effective.22,23 4 is an ATP-competitive inhibitor,
binding to the active site of mTOR with a Ki of 1.4 nM, while
achieving high selectivity versus PI3Ks (Ki > 200 nM),
24
although this selectivity profile has been put in doubt.25 This
candidate is currently under investigation for an array of
cancers, predominantly solid tumours. With phase I studies
Fig. 1 Structures of the first reported pyrazolo[3,4-d]pyrimidine kinase
inhibitors 1 and 2.
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in glioblastoma, lung cancer, liver cancer and other solid
tumours currently ongoing, it has already progressed to
phase II studies in pancreatic, breast, lung cancers and
leukaemia, administered both alone and in combination.23,26
Further studies have demonstrated efficacy in prostate
cancer.27 The structure activity relationships of 4 have been
further explored by chemists, with studies demonstrating
that small structural changes can significantly alter its
selectivity profile.28,29
Parsaclisib (otherwise known as INCB050465, 5, Fig. 2)
was first reported in 2014 by Incyte, being the product of a
medicinal chemistry programme originating from the PI3Kδ
inhibitor dezapelisib, which is currently undergoing phase II
clinical trials for lymphomas.20,30,31 Structural modifications
to dezapelisib, notably the alteration of the purine hinge-
binder in favour of a pyrazolo[3,4-d]pyrimidine, yielded a
series of highly potent PI3Kδ inhibitors, which will be
discussed later in this article.31 5, which possesses excellent
selectivity for PI3Kδ over the other PI3K isoforms, showed the
most promising pharmacological profile and was taken
forward for further evaluation. The PI3Kδ isoform plays a
central role in the signalling network that controls B-cell
growth, and it has been shown that mutations in this kinase
are responsible for the formation of B-cell cancers.32 5 has
entered clinical trials in a range of indications, such as
lymphoma, breast cancer, and other solid tumours, with
some success progressing through phases, particularly
against lymphomas.20
Umbralisib (otherwise known as RP5264, 6, Fig. 2) is an
investigational dual PI3Kδ/CK1 inhibitor, first disclosed in
2014, currently in phase III clinical trials for the treatment of
lymphomas, particularly for marginal zone lymphoma, which
has no current FDA-approved treatment.20,33 6 has been
shown to be an effective treatment of B-cell cancers, due to
its PI3Kδ activity. 6 also inhibits CK1, which is responsible
for mRNA translation, as well as having greater selectivity for
the PI3Kδ-isoform than other inhibitors.34,35 Studies
comparing the effect of 6 relative to idelalisib (the first PI3Kδ
inhibitor to be approved, which is structurally similar to 6),
attribute its greater efficacy against more aggressive
lymphomas to the dual inhibition of CK1 in conjunction with
PI3Kδ, and the subsequent reduction in the levels of the
c-MYC transcription factor.36 Following a successful phase I
study in patients with leukaemia and lymphoma, 6 passed
through a phase II study to phase III, where it has been
awarded breakthrough therapy status by the FDA.20,35,37
Pyrazolo[3,4-d]pyrimidines in
preclinical development
Pyrazolo[3,4-d]pyrimidines continue to be of great interest in
drug discovery programmes, especially those in cancer drug
discovery. In the next sections, we discuss recent publications
of anticancer kinase inhibitors featuring this scaffold,
grouped by the kinases which they inhibit.
ATR
Ataxia telangiectasia and rad-3 related protein (ATR) is a
member of the phosphatidylinositol-3-kinase-related protein
kinase (PIKK) family of serine/threonine protein kinases. ATR
senses DNA damage and triggers repair through cell cycle
arrest of damaged cells.38 Despite several ATR-inhibitors
currently undergoing clinical trials, none yet are approved.
Current compounds, such as ceralasertib (AZD6738) and
BAY1895344, are undergoing evaluation for the treatment of
leukaemia and lymphoma.39,40
The PIKK family has a degree of homology with the PI3K
family and these molecules can be used as a means for
guiding ATR inhibitor design.41 A library of PI3K and BTK
inhibitors was used by Ramachandran et al. to find ATR hits
through an screening campaign. Pyrazolo[3,4-d]pyrimidine 7
Fig. 2 Compounds currently approved or undergoing clinical trials for cancer treatment that contain the pyrazolo[3,4-d]pyrimidine scaffold
(highlighted in blue).
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was identified as of interest (Fig. 3), as in addition to being
the most potent ATR inhibitor, it also demonstrated
selectivity versus BTK and PI3Kδ. Small focussed libraries
were designed to explore structure activity relationships (SAR)
around the ring. Through several iterations of synthesis and
screening, 8 was identified with a high potency against ATR
(IC50 = 66.0 nM), a 3-fold improvement on the initial hit
(Fig. 3). The selectivity of 8 with respect to 394 other kinases
was determined. At 1 μM, 8 inhibited 23 kinases at levels
greater than 70%, with minimal activity against PI3Ks and
BTK, and activity primarily against other tyrosine kinases.42
BTK
Bruton's tyrosine kinase (BTK) is a key regulator in the B-cell
receptor (BCR) signalling pathway. BTK overexpression is
frequently observed in B-cell cancers such as lymphomas and
leukaemia.43,44 The BTK active site contains an exposed
cysteine residue which makes it possible for covalent
inhibition of the kinase.45,46 The approval of 3 triggered
numerous medicinal chemistry programmes aiming to
develop further BTK inhibitors as well as inhibitors of other
kinases containing conserved cysteine residues.45,47 While 3
is currently a highly successful treatment, it is only
moderately selective versus other kinases and has some off-
target toxicity, which is a result of the key cysteine residue
being conserved in other kinases, such as EGFR and ITK.
The first of these ‘second-generation’ BTK inhibitors was
acalabrutinib, which modified the structure of both the C3-
and N1-positions of 3 to improve BTK potency and
selectivity.48 The structures of the BTK inhibitors developed
over subsequent years frequently conserve the pyrazolo[3,4-d]
pyrimidine scaffold central to 3. Some studies have focussed
on exploring the properties of the Michael acceptor, through
modifications to the α,β-unsaturated carbonyl moiety, while
other studies have focussed on the ether-linked phenyl rings
in the northern region, which lie near the DFG motif. The
pyrazolo[3,4-d]pyrimidine scaffold has also been subject to
alteration, such as conversion to other pyrazolopyrimidine
isomers or heteroaromatic ring systems. However, these will
not be covered here.
Analysis of pyrazolo[3,4-d]pyrimidine BTK inhibitors
identifies some common characteristics; a northern region at
the C3-position of the central core that exploits a
hydrophobic pocket, the central core itself, and the Michael
acceptor warhead, which is attached to the core at the N1-
position by a linker.49 Several studies have focussed on the
warhead and have swapped the α,β-unsaturated carbonyl
moiety in favour of more reactive groups such as chloroacetyl
groups (Fig. 4). In one such study, the piperidine linked
warhead of 3 was changed for derivatives of the benzyl-linked
warhead found in the BTK inhibitor spebrutinib, yielding
lead compound 9. This compound maintained BTK-potency
relative to 3, and kinome profiling demonstrated a greater
selectivity for BTK over a range of kinases, including EGFR.49
Optimisation of 9 sought to modify the phenyl rings in the
C3-position of the molecule through the addition of pyridine
rings in the linker to improve binding. Although most of the
new derivatives were weakly potent for BTK, 10, which
incorporated a chloroacetyl warhead, demonstrated a low-
nanomolar potency against BTK, with improved anticancer
activity in a Mantle cell lymphoma cell line and improved
selectivity over other kinases.50
Further studies have examined the groups in the C3-
position, retaining the core and warhead key for BTK activity.
π-Stacking interactions in the distal phenyl ring were
explored by changing the linkers between the core and the
phenyl ring (Fig. 4). 11, with the phenyl linked to the core by
an alkynyl ether, showed high potency against BTK
comparable to 3, with an IC50 value of 7.95 nM, whilst
demonstrating a better physicochemical profile than the
approved drug.51 11 was further optimised through the
design and synthesis of 15 molecules containing alterations
to the warhead in the N1-position. One of the derivatives
synthesised, vinyl sulphonamide 12, demonstrated an
improved BTK IC50 than 3 at 4.2 nM. Despite this, upon
evaluation in two B-cell leukaemia lines, 12 did not show
effective antiproliferative activity. In contrast, another potent
BTK-active molecule from the series containing an acetamide
13 (IC50 = 11.1 nM), exhibited a low micromolar cytotoxicity
against B-cell cancer cell-lines.52 This is further proof of the
limitation of ranking compounds' potencies only by
biochemical assays against isolated proteins, as it overlooks
the capacity of the compounds to cross biological barriers.
Proteolysis targeting chimeras (PROTACs) have emerged
as a technology for selectively inhibiting a target by triggering
proteasomal degradation of proteins after E3-ligase mediated
ubiquitination.53,54 The PROTAC approach has been of
specific interest in cases of chronic lymphocytic leukaemia,
where drug resistance arises because of mutation of the
active cysteine residue to a serine residue preventing covalent
inhibition.55 To reduce off-target toxicity and to overcome
drug resistance, 3 has been used to develop a BTK targeting
PROTAC (Fig. 5). BTK PROTACs have been developed by
linking an E3-ligase cereblon ligand to the pyrazolo[3,4-d]
Fig. 3 Optimisation of pyrazolo[3,4-d]pyrimidines for the
development of ATR kinase inhibitors.
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pyrimidine core with a polyethylene glycol linker, attached at
the piperidine ring in the N1-position, replacing the covalent
warhead. An initial PROTAC developed, MT802 (14), degrades
BTK in cells at low nanomolar concentrations in vitro.
Fig. 4 Pyrazolo[3,4-d]pyrimidine inhibitors of BTK, MKK7 and EGFR derived from the first-in-class covalent BTK inhibitor 3.
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However, high clearance and a resultant low half-life in mice
discarded further preclinical development.55 Efforts have
been made to improve these properties, while retaining the
BTK-degradation properties, through the modification to the
cereblon ligand, by removal of one of the carbonyl groups
and the linking group to the glycol chain, yielding PROTAC
SJF620 (15). 15 maintained a similar level of BTK
degradation, and possessed a low clearance and a longer
half-life.56
CDK
The cyclin dependent kinases (CDKs) are a family of serine/
threonine kinases that are cell cycle regulators. Only 5 out of
Fig. 5 Design of PROTACs for the targeted degradation of BTK.
Fig. 6 Development of CDK inhibitors from existing pyrazolopyrimidine and purine CDK inhibitors.
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the 12 CDK isoforms are directly involved in the control of
the cell cycle. In cancer, dysregulation of the cell cycle results
in rapid and uncontrolled proliferation of cancer cells, as
well as resistance to treatment, making it an attractive target
for anticancer agents.57,58 First generation CDK inhibitors,
such as roscotovine and flavopiridol, were generally pan-CDK
inhibitors, and CDK2 was a common target across the class.
Given this lack of selectivity over non-oncogenic CDK
isoforms, few of these inhibitors progressed further in
clinical trials due to mild toxicity and poor efficacy.57 Second
generation CDK inhibitors have also been developed, and are
generally more selective. Three dual CDK4/6 inhibitors,
palbociclib, ribociclib and abemaciclib, have been approved
for the treatment of breast cancer.58
Existing suboptimal inhibitors such as roscovitine, led to
the design of further inhibitors, such as dinaciclib, which
contains a pyrazolo[1,5-a]pyrimidine, an isostere of the
pyrazolo[3,4-d]pyrimidine scaffold.59,60 Using dinaciclib as a
starting point, Hassan et al. designed a library of
pyrazolo[3,4-d]pyrimidines that incorporated benzene
sulphonamides in the N1-position (Fig. 6). Molecules
containing varied substitutions at the C4- and C6-positions
were synthesised, and screened in two cancer cell lines. The
two most promising molecules 16 and 17 were shown to
induce apoptosis. The most potent CDK2 inhibitor was 17
with an IC50 of 0.19 μM.
61
Further research by Cherukpalli et al. has sought to exploit
the pyrazolo[3,4-d]pyrimidine scaffold to generate CDK2
inhibitors. Based on existing pyrazolo[3,4-d]pyrimidines that
have been developed as kinase inhibitors, such as the series
of SRC family kinase inhibitors generated by Schenone et al.,
a series of 4,6-disubstituted pyrazolo[3,4-d]pyrimidines were
synthesised through incorporation of amine linked aryl
groups in the C4-position and aliphatic or aromatic groups in
the C6-position (Fig. 6). The molecules were screened against
ABL, CDK2 and two cancer cell lines. A thiophenethyl in the
C6-position was found to be essential for anticancer potency
and the substitution pattern in the C4-aryl moiety was
important for CDK2 inhibition. 18 showed the greatest CDK2
inhibition (IC50 = 5.1 μM) and it showed low-micromolar
anticancer activity.62 The initial pyrazolo[3,4-d]pyrimidine
SAR generated was taken forward to design further
compounds, with a series optimised from an initial set of
phenyl carbamoyl acetamide derivatives with a thioether
linkage. Through modification and derivatisation of the C4-
and C6-positions (Fig. 6), molecules were synthesised, and
screened for in vitro enzymatic and antiproliferative activity.
Several leads were identified and, of these, 19 demonstrated
the best CDK2 inhibition (IC50 = 6.8 μM) and low-micromolar
potency against two cancer cell lines.63
cMET
cMET is a member of the MET family of receptor tyrosine
kinases. cMET is a transmembrane receptor expressed on the
surface of cells that binds the hepatocyte growth factor (HGF)
ligand. While under normal conditions mediates the wound
healing response, abnormal cMET activation can promote the
development and progression of multiple cancers.64 The
HGF/cMET signalling cascade can stimulate downstream
pathways implicated in cancer progression, such as PI3K/
AKT, JAK/STAT, RAS/MAPK and SRC, which are responsible
for regulating proliferation, invasion, metastasis and other
hallmarks of cancer. cMET is frequently involved in the
development of drug resistance against these pathways,
associating it with poor prognosis and lower survival.64,65
Cabozantinib, 20, was the first example of a FDA approved
cMET inhibitor (Fig. 7). As a multi-targeting tyrosine kinase
inhibitor, 20 also inhibits VEGFR2 and other kinases such as
RET and AXL, and has been primarily used for the treatment
of renal cell carcinoma and liver cancers.66 Further
generations of cMET inhibitor have been developed, with
capmatinib being the first selective cMET tyrosine kinase
inhibitor approved, for resistant non-small cell lung cancer.65
Work by Wang et al. initially developed a series of
pyrrolo[2,3-b]pyridine derivatives from 20 (Fig. 7). These
molecules (21) maintained a key 5-atom linker between the
pyrrolopyridine core and the distal phenyl ring. Generic
structure, 21, was optimised through replacement of one of
the amine components of the urea linker for a triazole
Fig. 7 Development of c-MET inhibitors from 20.
RSC Medicinal Chemistry Review
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 0
8 
Se
pt
em
be
r 
20
20
. D
ow
nl
oa
de
d 
on
 1
0/
20
/2
02
0 
3:
44
:1
0 
PM
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online
RSC Med. Chem. This journal is © The Royal Society of Chemistry 2020
moiety. Further optimisation of 21 converted the
pyrrolopyridine to a pyrazolo[3,4-d]pyrimidine bearing a
triazole moiety with varied substitutions of the terminal ring.
The library of molecules was screened against breast, liver
and lung cancer cells to determine anticancer effect as well
as evaluating the cMET inhibition. 22 was shown to be the
most active of the pyrazolopyrimidine series with EC50 values
of 10 μM or less, demonstrating antiproliferative effect in
cancer cells. Evaluation of the cMET IC50 in biochemical
assays showed that 22 possessed moderate potency with a
low micromolar IC50.
67
EGFR
Epidermal growth factor receptor (EGFR) is a family of
transmembrane receptor tyrosine kinases comprising of
EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4.
The EGFR family are major contributors to complex
signalling cascades that control cell growth, differentiation,
migration, and survival.68 Mutations and aberrations in EGFR
activity play an important role in many malignancies,
including breast, lung, and oesophageal cancers, amongst
others, making EGFR an attractive target for intervention.69,70
Gefitinib, first characterised in 1996, was the first EGFR
inhibitor to be approved by the FDA, for the treatment of
NSCLC, in 2003. Further EGFR inhibitors, such as erlotinib,
an anticancer drug used for breast and pancreatic cancers,
and lapatinib followed soon after.68,69
Engel et al. used 1 and 3 as starting points for EGFR
inhibitor design. A structure-based approach was used to
design a small focussed library of inhibitors which explored
the C3-position that extends towards a methionine residue in
the active site. A key component within the structure of the
most active inhibitors was the inclusion of a piperidine-
linked Michael acceptor in the N1-position, which facilitates
covalent binding to a conserved cysteine residue present in
the active site of EGFR, much like that of BTK. Several
molecules, of which the lead molecule was 23 (Fig. 4), were
highly potent in a set of cancer cell lines and presented
nanomolar potency against EGFR in biochemical assays.
Further analysis of the physicochemical properties in vitro
and in vivo demonstrated that 23 possessed the best overall
profile, displaying a high kinetic solubility as well as an
excellent permeability.71
Maher et al. designed a series of dual EGFR/ErbB2
inhibitors through the isosteric replacement of the
quinazoline core of lapatinib and erlotinib, with a
pyrazolo[3,4-d]pyrimidine core. The substitutions around this
core primarily focussed on the incorporation of a library of
substituted arenes in the C4-position linked by a variety of
different nitrogen-containing moieties. The 4-fluorobenzene
moiety in the N1-position was maintained in the library. The
compounds synthesised were screened against a panel of 60
cancer cell lines for percentage growth inhibition, and of the
compounds screened, compound 24 showed moderate
anticancer activity across the panel (Fig. 8). In several cell
lines 24 demonstrated greater potency than the control,
erlotinib. Further evaluation demonstrated sub-micromolar
potency against the EGFR and HER2 kinases (IC50 = 186 and
254 nM, respectively), demonstrating its retention of dual
inhibition, as well as exerting its antiproliferative activity by
inducing cell cycle arrest.72
Abdelgawad et al. designed a series of ATP-competitive
inhibitors based upon a series of successful
anilinoquinazoline-containing compounds that reached and
succeed in clinical trials, such as erlotinib and gefitinib.
These molecules incorporated this moiety into the
pyrazolo[3,4-d]pyrimidine scaffold, creating libraries which
focussed predominantly on the substitutions to the distal
aromatic ring. The compound library was screened in three
cancer cell lines to evaluate their anticancer effect, with
several molecules presenting low-micromolar potencies. Lead
molecules were assayed against a panel of growth factor
receptor kinases, and lead molecule 25 (Fig. 8) was identified
as a selective EGFR inhibitor with low micromolar IC50 (4.18
μM).73
JAK
The Janus kinases (JAK1, JAK2, JAK3 and TYK2) are a family
of intracellular tyrosine kinases that regulates cell
proliferation, differentiation, survival, and embryological
processes.74 Oncogenic mutations can result in activation of
the JAK–STAT pathway, contributing to the progression of
several cancers, including haematological malignancies and
some solid tumours.75 The JAK active site contains a
conserved cysteine residue, like that of BTK and EGFR, and
therefore covalent inhibition of this kinase is possible. JAK
inhibitors with a range of selectivity profiles have been
described, with seven inhibitors currently approved for
clinical use and several others in clinical trials. Several of
these inhibitors are indicated for the treatment of various
cancers. Ruxolitinib, a JAK1/2 inhibitor, was approved for the
Fig. 8 EGFR inhibitors developed through bioisosteric replacement of
the quinazoline moiety of approved EGFR inhibitors erlotinib and
lapatinib.
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treatment of myelofibrosis – a rare form of bone marrow
cancer – in 2011 and is currently being investigated for the
treatment of further B- and T-cell cancers. A second JAK2
inhibitor for the treatment of myelofibrosis, fedratinib, was
approved in 2019.
The homology that exists between kinases with exposed
cysteine residues has facilitated the design of JAK inhibitors
such as 26 (latterly known as JAK-3-IN-1, Fig. 9) from covalent
EGFR inhibitors, and it was identified as a moderately-
selective JAK3 inhibitor, with limited potency versus EGFR.
Further optimisation of this compound yielded 27, a covalent
JAK3 inhibitor, which had an improved IC50 value of <0.5
nM, 70-fold more potent than for EGFR.76 Yin et al. used
these molecules as well as existing JAK-inhibitor SAR to
replace the central pyrimidine ring system of 27, with a
bioisosteric pyrazolo[3,4-d]pyrimidine ring system in a
scaffold-hop, giving parent compound 29 (Fig. 9), which
showed a moderate JAK3 activity. Through molecular
reconfiguration transferring the tail region to the C3-position
of a 4-aminopyrazolopyrimidine core, 30, the JAK3 potency
was improved 2-fold from 29. Using this structure and that of
3, further optimisation of the alkyl chain of the tail and the
linker to the Michael acceptor was achieved through several
rounds of synthesis. Lead molecule 31 was identified with a
JAK3 IC50 value of 6.2 nM, which was comparable to 26.
Furthermore 31 demonstrated unique selectivity over the
other JAKs and also BTK and in in vitro studies it showed
excellent antiproliferative activity in T cell cancer lines.77
Using moderately potent JAK3 pyrazolopyrimidine 29 as a
starting point (Fig. 9), further work was carried out to develop
Fig. 9 Development of selective JAK-family inhibitors from the parent molecule 26.
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more selective JAK3 inhibitors. Through rearrangement of
the functional groups, in which the orientation of the
pyrazolopyrimidine was shifted, moving the ‘tail-group’ to
the C6-position as opposed to the C4-position, a novel library
was obtained and studied further in a medicinal chemistry
campaign in which the nature of the tail and the Michael
acceptor groups were varied, according to literature examples.
From this study, the most potent molecule was the direct
rearrangement of 29 into 32. 32 was highly potent and
selective for JAK3 (IC50 = 1.5 nM and >376 fold selectivity
over the other JAK isoforms) and further evaluation showed
that it is selective for JAK3 over other kinases featuring a
reactive cysteine group, such as the TEC family, EGFR and
BTK. The lead molecules were evaluated for activity against
T-cell cancer cells and were shown to display low-micromolar
antiproliferative activity.78
Currently there are several JAK2 inhibitors in clinical use,
ruxolitinib, baricitinib and fedratinib, with further examples
in clinical trials. Yin et al. detailed the development of
selective JAK2 inhibitors with the pyrazolo[3,4-d]pyrimidine
scaffold, derived from the structure of 26, as in their previous
work, and aimed to exploit an acrylamide electrophile to
form a covalent bond with a cysteine residue in the ATP site
of JAK3. Mimicking the strategy to identify 31, alterations to
the tail region in the C4-position yielded 33 (Fig. 9), with no
improvement in JAK3 potency. To develop more effective
JAK3 inhibitors, a series of 1H-pyrazolo[3,4-d]pyrimidin-4-
amine analogues were synthesised exploring the pyrazole
ring, which also included a relocation of this heterocyclic
group from the amino group at C4 to the C3 position of the
pyrazolo[3,4-d]pyrimidin-4-amine. The compound library
exhibited moderate JAK2 and JAK3 inhibitory activity with
selectivity over JAK1. A further library was designed, and this
resulted in reductions in the JAK3 potency and the
enhancement of the JAK2 potency. This identified lead
compound 34 that had a JAK2 IC50 value of 6.5 nM and >36-
fold selectivity over the other JAK kinases.79
MKK7
Mitogen-activated protein kinase 7 (MKK7) is a regulator of
the c-Jun NH2-terminal protein kinase (JNK), a member of
the MAPK family that regulates cell proliferation,
differentiation, and apoptosis. MKK7 is a sensor of cellular
stress, particularly associated with onogenesis.80 While MKK7
is implicated in T-cell acute lymphoblastic leukaemia,
myeloma and lung cancers, its functions are context
dependent and can be involved in cancer progression but
also act as a tumour suppressor in many instances.80,81
Consequently, the development of MKK7 inhibitors has not
been extensively studied, and no MKK7-inhibitors have
entered clinical trials. Predominantly interest in these
inhibitors is as probes to fully elucidate MKK7 function.
MKK7 contains a cysteine residue, so covalent inhibition of
the kinase has been proposed. However, the cysteine is highly
conserved, so covalent inhibition is not as effective.
Furthermore, achieving selectivity for MKK7 is challenging
given significant homology with MAP2Ks.80
3 and some derivatives display off-target MKK7 activity
and has been used as a starting point for the development of
MKK7 inhibitors. 23, a dual EGFR/MKK7 inhibitor, was used
by Wolle et al. to design and synthesise a small focussed
library of pyrazolo[3,4-d]pyrimidines to exploit the homology
between the binding-pockets of the EGFR and MKK7 active
sites (Fig. 4). Through modifications and optimisation of the
C3-position, para-ketobenzene 35 was identified as a lead
molecule, with an IC50 value against MKK7 of 10 nM. Further
evaluation of this molecule in a panel of 320 kinases
demonstrated excellent selectivity with only seven other
kinases possessing inhibition greater than 50%,
predominantly those which possess a reactive cysteine
residue.82 The library of MKK7 inhibitors containing Michael
accepting groups were further studied, and the crystal
structures solved to determine their binding modes. The
most potent of the molecules studied contained the
acrylamide group in 3, with lead molecule 36 containing this
group as its warhead and a phenol in the C3-position.
Notably, 36 exhibited a greater MKK7 potency than 3 (IC50 =
8.6 nM).83
mTOR
The mammalian target of rapamycin (mTOR) is a serine/
threonine protein kinase that operates as the catalytic
subunit of two protein complexes, mTORC1 and mTORC2,
that act as sensors to integrate multiple extracellular and
intracellular signals from the to coordinate the cell cycle.84,85
While increased mTOR expression and/or activation is
observed in several cancers,85,86 the kinase itself is rarely
directly mutated, with overactivation being triggered by
mutations in upstream regulators, such as EGFR, PI3Ks, AKT,
PTEN, RAS and RAF. Given its role as master regulator of
many oncogenic signals, clinical evidence of mTOR activity
has been found in over half of all cancers, making it an
attractive target.87 There are two main classes of ATP
competitive mTOR inhibitors: the dual mTOR/PI3K
inhibitors, which arise as a result of significant similarities
between these kinases, and selective mTOR inhibitors, which
are more selective but unlike the rapalogs can inhibit the
function of both mTOR complexexes. Both classes of ATP-
competitive inhibitor have generated molecules entering
clinical trials, with dactolisib and sapanisertib (4) examples
of each respectively.86,87 The selective mTOR inhibitors, of
which 4 is a leading example, have been frequently designed
around the pyrazolopyrimidine core, such as a series of
molecules designed by Intellikine.88,89
Fraser et al. recently identified a highly selective mTOR
inhibitor, eCF309 (38), from a chemocentric phenotypic drug
discovery approach focussed on the pyrazolo[3,4-d]pyrimidine
scaffold. Hit molecule 37 (Fig. 10), first identified in a
phenotypic screen, exhibited an IC50 (mTOR) of 328 nM.
Optimisation of the C3- and N1-positions, incorporating
RSC Medicinal ChemistryReview
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 0
8 
Se
pt
em
be
r 
20
20
. D
ow
nl
oa
de
d 
on
 1
0/
20
/2
02
0 
3:
44
:1
0 
PM
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online
RSC Med. Chem.This journal is © The Royal Society of Chemistry 2020
different aryl moieties into the C3-position and substituted
alkyl chains into the N1-position, yielded three lead
molecules with low nanomolar potencies in breast and
prostate cancer cell lines. The lead molecules all contained
the characteristic benzo[d]oxazole group of 4 and were shown
to induce cell cycle arrest in the cancer cell lines used. The
kinome selectivity was determined, and 38 was identified as
the most potent against mTOR (IC50 = 15 nM), as well as
being highly selective versus other kinases. Further
optimisation to the molecule's N1-position was attempted to
explore potency and selectivity. While compounds with
superior potency than 4 were identified, they displayed dual
inhibition of mTOR and PI3Ks. The structural similarities
between these dual inhibitors and 4 shed doubts over the
supposed selectivity of 4 over PI3Ks. 38, which features an
ethyl acetal group at the N1-position of the ring, remained
the most selective lead of the series.25 Subsequent
investigations with an in-house library of 100 pyrazolo[3,4-d]
pyrimidine derivatives, found the same family of compounds
as promising antiproliferative leads against glioblastoma cell
lines, including patient derived cells.29
PAK
The p-21 activated kinases (PAKs) are a group of six serine/
threonine kinases responsible for the regulation of numerous
signalling pathways involved in proliferation, survival and
motility, amongst others.90,91 While they are rarely directly
mutated in cancer, the PAK kinases are subject to
dysregulated expression and amplification, leading to
uncontrolled cell proliferation, altered cell signalling, drug
resistance and reduced levels of immune response through
the activation of downstream signalling pathways, such as
the PI3K/AKT pathway.92 Therefore, PAK inhibitors have been
extensively studied and several inhibitors have reached early
phase clinical trials. PF-3758309, a group II PAK4 inhibitor,
was the first to reach clinical trials. However, it failed due to
poor pharmacokinetic properties. The allosteric inhibitor
KPT-9274, also a PAK4 inhibitor, is currently under
evaluation in clinical trials for solid malignancies.93
ZMF-10 (40) was identified as a sub-micromolar PAK1
inhibitor (Fig. 11), possessing moderate selectivity over other
PAKs. 40 demonstrated an antiproliferative effect in breast
cancer cell lines. The molecule was developed from
ZINC194100678 (39), a hit identified through a virtual high-
throughput screening (HTS) campaign, through docking of
the molecules into a PAK1 homology model. A hydrophobic
pocket identified by these studies aided the design of a series
of molecules exploiting this region through modifications at
the C4-position of the pyrazolo[3,4-d]pyrimidine scaffold.
Following several rounds of optimisation, the lead molecule
40 was identified, which was confirmed as a PAK1 inhibitor
and suppressed the proliferation of 4 cancer cell lines
through the induction of apoptosis.94
Fig. 10 Development of potent and selective inhibitors of mTOR and SFK from the promiscuous kinase inhibitor 1.
Fig. 11 Design of PAK inhibitors through the modification of a virtual
screening hit.
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PI3K
The phosphatinidyl-3-kinases (PI3Ks), of which there are
several isoforms (α, β, γ and δ), are responsible for the
conversion of PIP2 to PIP3, which then initiates a complex
network of downstream signalling.95 The α/β-isoforms are
widely expressed, whereas the δ/γ-isoforms are predominantly
expressed in B- and T-cells. Mutations in PI3Ks are observed
in several different cancers, including glioblastoma, breast,
ovarian, bladder, amongst others.95–97 The key challenge to
the development of isoform selective PI3K inhibitors is that
PI3Ks share homologous ATP-binding pockets resulting in
non-specific pan-PI3K inhibitors, which display off-target
effects. Idelalisib, approved in 2014 for the treatment of
chronic lymphoblastic leukaemia, was the first PI3K inhibitor
to reach the market.97
The pyrazolo[3,4-d]pyrimidine core is found in several
recent PI3K inhibitors, designed as derivatives of the purine
scaffold of the selective PI3Kδ-inhibitor idelalisib (41) and
the dual PI3Kδ/γ-inhibitor duvelisib (42). Parsaclisib (5), a
pyrazolo[3,4-d]pyrimidine inhibitor currently being evaluated
in clinical trials, was designed to improve the selectivity and
Fig. 12 Development of PI3K inhibitors based on PI3Kδ-inhibitors 41 and 42, yielding selective PI3K-δ inhibitor 5 and dual PI3K-δ/γ inhibitors.
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PK properties of dezapelisib (43), a purine-containing
derivative of 41 and 42 (Fig. 12). Through a systematic SAR
study of 43, purine lead 44 was identified. The central purine
core of 44 was broken down and reassembled into a
pyrazolo[3,4-d]pyrimidine ring system, whilst conserving its
binding interactions. Initially there were promising
improvements to the selectivity for the δ-isoform and the
potency versus existing inhibitors. Further alterations to
substituents around the pyrazolopyrimidine core removed
hERG channel inhibition liabilities and resulted in the
discovery of 5, which exhibited efficacious reductions in the
growth of tumours and low preclinical toxicity.31
In a series of novel quinazolinone compounds which
demonstrated potent PI3K-δ inhibitory activity, Ma et al.
incorporated the pyrazolopyrimidine core as a replacement
for amine-linked purine cores in the approved inhibitors.
The most potent PI3Kδ inhibitors, 45 and 46 (Fig. 12), were
evaluated for their selectivity against other isoforms of PI3Ks,
with 45 being selective for the δ-isoform (40–3630 fold) and
46 being a selective dual inhibitor of δ/γ over the other
isoforms (820–1400 fold). The compounds demonstrated
potent antiproliferative effects in a B-cell leukaemia cell line.
Evaluation of PK properties identified that 46 was most
suitable for further development due to its low clearance and
good bioavailablity.98
ZSTK474 (47, Fig. 13) is a further example of a potent ATP-
competitive pan-PI3K inhibitor selective over other protein
kinases, currently undergoing early phase clinical trials.
Through modelling of 47, Gamage et al. identified one of the
two morpholines was not required for maintenance of the
binding interactions and used this region for further
optimisation through alterations to this position. Piperazinyl
sulphonamide 48 is a potent dual inhibitor of PI3K-α/δ. The
central pyrimidine ring of this structure was further
optimised to a pyrazolo[3,4-d]pyrimidine, as well as to some
purines. From the pyrazolopyrimidine derivatives
synthesised, compounds 49 and 50 (Fig. 13) were shown to
be potent and selective against specific isoforms of PI3K. 50
showed an IC50 value of 2.6 nM against PI3Kα with selectivity
over other isoforms. Despite this high potency and selectivity
profile, the purine analogues synthesised were more tractable
for further development. However, the high potency of 49
and 50 demonstrates the effectiveness of the
pyrazolopyrimidine scaffold to make PI3K inhibitors, serving
as tool compounds.99
RAF
The RAF kinases (ARAF, BRAF and CRAF) are important
components of the MAPK/ERK signalling pathway. This
pathway is one of the most frequently mutated in cancer, and
is triggered through the activation of RAS, which in turn
activates RAF. BRAF is the most frequently altered protein
downstream of RAF, activated in 7–10% of all cancers.100,101
BRAF mutations increase MEK/ERK activity, promoting
tumour proliferation and growth. 90% of the BRAF mutations
comprise of the specific BRAFV600E point mutation, which is
a contributor to uncontrolled proliferation and
angiogenesis.102 Sorafenib (51), a protein kinase inhibitor
with activity against VEGFR, PDGFR and RAF kinases and
approved for the treatment of kidney and liver cancers, was
initially developed for inhibition of RAF. It exhibits selectivity
Fig. 13 Design of selective PI3K-α inhibitor from pan-PI3K inhibitor 47.
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for CRAF over BRAF. However, its lack of selectivity over other
kinases has resulted in a low safe dose and consequently a
loss of efficacy in some patients. More recent examples of
RAF inhibitors include vemurafenib and dabrafenib, and
these inhibitors are far more specific and effective, especially
in melanomas which are driven by the BRAF-mutant
BRAFV600E.102
Fu et al. used 51 to design analogues, incorporating a
pyrazolo[3,4-d]pyrimidine in place of the pyridine (Fig. 14).
The substitution pattern on the distal aromatic ring, linked
to the core through the urea, was altered to explore the
scaffold SAR. The N1-position was also explored, through the
addition of some substituted alkyl groups. Three lead
compounds, 52, 53 and 54, were identified, exhibiting potent
BRAFV600E inhibition. The antiproliferative effect of the leads
were evaluated in human cancer cell lines, with 53 being
more effective than 51. Notably, 53 was also more potent
than 51 versus BRAFV600E at 23.6 nM. 53 was further evaluated
against other kinases, confirming potent inhibitory activity
against other RAF isoforms, but no significant activity against
other kinases tested, indicating 53 is a potent and selective
pan-RAF inhibitor.103 The inhibition of RAF shows a degree
of synergy with inhibition of VEGFR, and it has been
proposed that inhibition of RAF, which contributes to tumour
growth, coupled with inhibition of VEGFR, which contributes
to angiogenesis (providing the tumour with nutrients), would
be an effective way to treat some cancers.104 53 has been
subject to further optimisation, to develop a dual BRAF/
VEGFR inhibitor through improving the low VEGFR
inhibition while maintaining RAF inhibition. Modelling of 53
into the crystal structure of VEGFR indicated good overlap of
the pyrazolopyrimidine into the ATP pocket, with the urea
region being required to enhance binding. The rigidity of the
urea region was enhanced by scaffold hopping with an
aminobenzoxazole or an aminobenzimidazole ring, which
linked to a distal aromatic ring (Fig. 14). The target
compound library, which varied the substitution of the distal
ring system, was screened against BRAFV600E and VEGFR2
with 51 as a positive control. Several compounds showed
high inhibition of both kinases, comparable to the control.
55 showed sub-micromolar potencies against both kinases
(0.171 and 0.779 μM respectively), as well as effective
antiproliferative properties in several cancer cell lines. The
kinome selectivity of 55 showed little to no inhibition of a
range of kinases even at the highest concentration, except
CRAF. 55 was later shown to be a cell cycle arrestor in HUVEC
cells.105
Zhang et al. have recently developed a new series of
pyrazolo[3,4-d]pyrimidine inhibitors that possess excellent
selectivity for RAF kinases. Using an existing library of
promiscuous 3-alkynyl-pyrazolo[3,4-d]pyrimidine BRC-ABL
inhibitors, such as 56, a strategy of rigidification was used to
restrict the inhibitory profile to more flexible kinases
(Fig. 15). Alkyne-linked naphthyl, isoquinoline and
Fig. 14 Development of BRAF kinase inhibitors derived from 51. Subsequent optimisation yielded a dual BRAF/VEGFR inhibitor.
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quinazoline pyrazolopyrimidines were designed from 56,
synthesised and screened for activity against BRAF and
growth inhibition. The quinazolines were the most potent,
with 57 exhibiting the best potency against BRAFV600E, with
an IC50 value of 8 nM. The kinase selectivity profile of 57
against 245 kinases showed only four kinases including BRAF
and CRAF were inhibited by over 85%. Evaluation in
BRAFV600E mutant cancer cells indicates that 57 can be
potentially effective against BRAF mutant cancers.106
RET
RET is a receptor tyrosine kinase activated by a family of
extracellular signalling molecules known as the GDNFs.
Binding to its ligands homodimerises RET, which in turn
activates downstream signalling pathways such as MAPK and
PI3K/AKT. Overexpression and activation of RET are present
in the pathogenesis of many human cancers, particularly
thyroid, lung and some brain cancers.107,108 In 2019, the FDA
approved selpercatinib as the first selective RET-inhibitor for
the treatment of thyroid cancer and non-small cell lung
carcinoma (NSCLC). Prior to this, two multi-kinase inhibitors
that targeted RET had been approved for use in thyroid
cancer, cabozantinib (20) and vandetanib. However, these
inhibitors possess off-target effects against VEGFR and other
kinases, leading to undesirable side-effects in the clinic.109
The first pyrazolo[3,4-d]pyrimidine kinase inhibitor, 1, has
been shown to possess activity against RET.110 Wang et al.
identified two further pyrazolopyrimidines, 58 and 59
(Fig. 16), with nanomolar potency against RET and high
selectivity against VEGFR2. However, this potency was not
demonstrated in cellular assays. The leads were optimised
through the design of three compound libraries, introducing
modifications through ring-closing, addition of new
functional groups and linkers and the addition of amides to
exploit a hydrophobic pocket. The compounds were screened
for RET inhibition, and the most potent series were the
isoxazole ring analogues. These analogues explored the
functional groups appended to this ring and the most potent
was 60, whose IC50 value was 61 nM. Studies of 60 identified
that it was selective for RET over VEGFR2, and also inhibited
phosphorylation of STAT3 and AKT, downstream effectors of
RET signalling.111
SFK and ABL
The SRC-family kinases (SFK) comprises a group of nine non-
receptor tyrosine kinases: SRC, YES, FYN, FGR, LCK, HCK,
BLK, LYN and FRK. This enzyme family plays a key role in
the transduction of a wide range of extracellular signals, via
receptor tyrosine kinases, cell-to-cell and extracellular matrix-
to-cell communications. While this family of kinases is not
frequently mutated, it is central for the transmission of many
oncogenic signals, promoting survival, angiogenesis,
proliferation and invasion.112 Activation of SRC itself is
observed in half of all cancers, making it an attractive target
for cancer therapy.112,113 Numerous SFK inhibitors have been
Fig. 15 Design of selective RAF inhibitors from promiscuous inhibitors through a strategy of rigidification.
Fig. 16 Design and synthesis of pyrazolo[3,4-d]pyrimidine RET
inhibitors.
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evaluated for the treatment of cancers in clinical trials.
Dasatinib was the first approved inhibitor of SRC, although
because of its promiscuity it also inhibits many other
kinases, including ABL. Abelson tyrosine kinases 1 and 2 (a.
k.a. ABL and ARG, respectively) are implicated in processes of
cellular differentiation, division, adhesion, and stress
response. In chronic myeloid leukaemia (CML), a
chromosomal translocation occurs to generate a new fusion
gene, BCR-ABL, which is transcribed into the constitutively
active fusion protein BCR-ABL,114 being the main driver of
this disease. Dasatinib was approved for the treatment of
several forms of leukaemia, including CML, due to its
capacity to inhibit BCR-ABL-positive cancers, and it is
undergoing evaluation for use in lymphomas, breast, prostate
and other cancers in clinical trials. Further dual SRC/ABL
inhibitors have since been evaluated in clinical trials and
gained approval, including bosutinib.15,115 However, none
have yet been approved for their direct treatment of SRC-
driven cancers, probably due to their promiscuity.
Studies conducted by the Schenone Lab, initially based on
the promiscuous inhibitors 1 and 2, resulted in the
generation of a large library of pyrazolo[3,4-d]pyrimidines,
many of which have been published (Fig. 17). In 2008 study,
they disclosed a dual pyrazolo[3,4-d]pyrimidine inhibitor of
SRC and ABL, 61.116 A later lead optimisation campaign
sought to improve the physicochemical properties of 61,
while maintaining its dual inhibitory activity. Modelling
identified that different polar moieties could be incorporated
in the C4- and C6-positions of the scaffold, which were
solvent exposed, thereby improving the water solubility and
ADME properties. The compound library synthesised largely
retained the dual SRC/ABL inhibitory profile upon biological
evaluation. The lead compounds were investigated for
antiproliferative properties in a panel of leukaemia cell lines.
Further evaluation of the most promising compounds was
carried out under hypoxic conditions, facilitating the
identification of the most promising leads; 62, 63 and 64
(Fig. 17), as optimised analogues of 61, with improved ADME
properties and favourable inhibitory properties.117 The crystal
structure of the compound 63 bound to SRC was used to
design modifications to the amine-linked benzene in the C4-
position. In parallel to these optimisations, alterations were
made to the side chain in the C6-position. The compound
library was screened in vitro to determine SRC inhibitory
activity and cellular viability in neuroblastoma cells. The lead
compound from the screens, 65, demonstrated greater
potency than the starting compound in neuroblastoma
cells.118
One of the challenges in finding selectivity between ABL
and SRC is the significant levels of homology that exist
between them. As a result, screening of the
pyrazolopyrimidine library against ABL in silico identified
several hits, such as 66, another derivative of 60 from the
2008 study, which was used to design a small focussed library
of ABL inhibitors. The lead molecule from this series, 67,
demonstrated nanomolar potencies against ABL, SRC and the
BCR-ABL mutant T315I, which is one of the mutants
responsible of the acquired resistance to the 1st generation
BCR-ABL inhibitor imatinib. A dual inhibitor of BCR-ABL and
its mutant T315I would provide a better standard of
treatment. In vivo studies of 67 in mice inoculated with 32D-
T315I cells showed that those treated showed a significant
reduction >50% in tumour size with respect to the
placebo.119
For the treatment of heterogeneous lymphomas and other
B-cell cancers, it is proposed that inhibition of multiple
targets could provide a greater therapeutic benefit for
patients, due to complex mutational pathways present in
these cancers. In B- and T-cell tumours mutations in FYN,
BLK and LYN can coexist, and it was postulated that an
inhibitor of these three targets would demonstrate greater
efficacy. 68 (Fig. 17), a FYN inhibitor first identified in 2015,
was used as the starting point for the development of a
multitarget inhibitor. The compound was modelled into the
protein structures to identify areas that could be exploited for
co-inhibition of the kinases. The phenyl ring in the C3-
position of the pyrazolo[3,4-d]pyrimidine core was selected
for modification given its position in the inner side of the
ATP binding pocket. Some of the 12 synthesised derivatives
also examined the chlorine group in the N1-sidechain. A
phenotypic screen against different cancer cell lines (B-cells
and T-cells) identified the lead 69 with low micromolar
potencies across all the cell lines. Kinome screening
demonstrated that the compound was a multitarget inhibitor
of FYN-BLK-LYN with comparable potencies across the three
kinases.120
ATP-competitive SRC inhibitor 70 (Fig. 17), a derivative of
63, has been studied as a potential treatment for
glioblastoma, both in vitro and in vivo, demonstrating good
growth inhibition effects, while also being well tolerated and
having low off-target toxicity.121 70 has been evaluated in a
series of invasive patient-derived glioblastoma cell lines, two
from the invasive region and a further obtained from the core
region of the tumour. The compound demonstrated low
micromolar IC50 values (7–11 μM) against the three cell lines
studied.122 A prodrug strategy was used to improve the
solubility of 9 compounds from the pyrazolopyrimidine
library, including 70, through addition of a water-solubilising
group containing a N-methyl piperazine. The prodrug of 70
was the most efficient and demonstrated a comparable
efficacy to 70 in vivo in an orthotopic model of glioblastoma
multiforme (GBM).123
Using ligand-based inhibitor design and phenotypic
screening cooperatively and starting from the promiscuous
inhibitor 1, a series of pyrazolo[3,4-d]pyrimidines were
synthesized and tested against breast cancer cells by Fraser
et al. (Fig. 10). After several iterations consisting of design,
synthesis and phenotypic screening of focussed libraries (up
to 12 compounds per round), a family of highly selective SRC
inhibitors was identified. The chemical strategy primed the
incorporation of flexibly linked solubilising groups to the N1-
position of the pyrazolopyrimidine scaffold, aiming to
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enhance the physicochemical properties of 1 and to explore
SAR within a chemical space with freedom to operate.
Structural evolution was based on anticancer potency against
ER+ and triple negative breast cancer cells, thus
discriminating compounds with low cell permeability and
inhibitors of pathways not involved in these cancer subtypes.
Fig. 17 Design and evolution of inhibitors of SFK and ABL from the promiscuous inhibitor 2.
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Hit molecule 71 was identified for further optimisation of the
p-tolyl group in the C3-position, since this position is key for
the determination of kinase selectivity. Further rounds of
optimisation inspired in the works of Schenone and others,
resulted in the discovery of the lead inhibitor eCF506 (72).
Further optimisation attempts resulted in a wide range of
compounds with different activities, but negligible or no
improvement of potency. 72 was further evaluated for kinase
selectivity, demonstrating high SRC potency (IC50 = <0.5 nM)
and >950-fold selectivity over ABL and other kinases. Given
its excellent physicochemical properties and promising
in vitro DMPK profile, 72 was further evaluated in cancer
models and in vivo (zebrafish and mice).113 Mirroring the
activity of ABL/nonSRC inhibitor imatinib, 72 is the only
in vivo active SRC inhibitor with selectivity over ABL.
TAM
The TAM family of kinases, comprising of TYRO3, AXL and
MER, are a group of receptor tyrosine kinases that are
amplified in an array of solid and haematological
malignancies. Amplification or overactivation of TAM kinases
triggers downstream signalling associated with uncontrolled
proliferation and survival.124 In cancer, TAM kinases are able
to supress tumour immunity, as well as contributing to drug
resistance. AXL is the most frequently amplified of the TAM
kinases.125 The FDA has approved some multi-kinase
inhibitors, such as cabozantinib (20), which has moderate
AXL activity. Further compounds are under preclinical and
clinical evaluation for a variety of cancers, including several
compounds designed specifically for TAM kinases.66,126
Wang et al. focussed on the development of inhibitors of
kinases of the TAM family starting from a weak MER
inhibitor, 73 (Fig. 18), yielding numerous promising
inhibitors for the treatment of various forms of leukaemia,
one of which has progressed to clinical trials.127 Through use
of a targeted-discovery approach, derivative 74, a
pyrazolo[3,4-d]pyrimidine heterocycle was proposed, and
structural modelling indicated that modifications to three
independent sites, the N1-, C3- and C6-positions would
enable optimisation of the scaffold for the inhibition of
MER. Optimisations of these positions yielded UNC569 (75),
which had good potency and selectivity for MER, while also
maintaining advantageous DMPK properties.128 Undesirable
activity towards the hERG ion channel made 75 unsuitable
for further clinical development given the risk of
cardiotoxicity associated to this inhibition. The primary
amine of the appending group in the N1-position was
postulated to contribute to off-target hERG activity. Alteration
to the groups here tuned out the hERG inhibition and further
optimisation to the C3-position through introduction of a
sulphonamide yielded the inhibitor UNC1062 (76), which had
improved selectivity and potency, but a poor PK profile.129
Through work to improve the PK profile of 76 by lowering of
the lipophilicity of the molecule and reduction of molecular
weight through removal of the morpholine and subsequently
the sulphonamide, as well as removal of a nitrogen from the
pyrazolopyrimidine core, UNC2025 (77) was discovered
(Fig. 18). 77 possessed a greatly improved PK profile while
maintaining the potency, and was subject to a scale-up and
further in vivo investigations which demonstrated effective
inhibition.130 77 progressed to a clinical trial and
demonstrated effectiveness in acute myeloid leukaemia
patients.127
Myers et al. used a chemocentric phenotypic drug
discovery approach to develop a series of molecules based on
Fig. 18 Development of Mer kinase inhibitors by the Wang group
leading to clinical candidate 77.
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75, a compound reported by Wang et al. that possessed
similar potency against MER and AXL. By modifying the
groups in the N1- and C3-positions with substituted alkyl
groups and aromatic substituents respectively, a library of
6-methylaminopyrazolo[3,4-d]pyrimidines were generated
(Fig. 19). Screening against AXL-expressing and non-
expressing cancer cells was used to bias compound selection
and evolution towards AXL inhibition. Lead molecule
eSM134 (78, IC50 = 380 nM) is of note as it inhibits AXL with
great selectivity over other TAM kinases, and other RTKs. A
further molecule of interest from this library was the FTL3
inhibitor eSM156 (79), which possessed an IC50 value of 1.4
nM versus FTL3, and sub-micromolar potencies against
leukaemia cell lines.131 eSM119 (80) also demonstrated
promising activity against three oncogenic kinases (AXL/
FTL3/RET) with sub-micromolar potencies. 80 was optimised
for AXL-selectivity through a strategy of macrocyclization
(Fig. 19). Macrocycles of 12 atoms or more may demonstrate
medicinal properties, often because of constrained rotational
degrees of freedom. Loratinib is an example of a recently
approved macrocyclic kinase inhibitor. Exploitation of the
triazole moiety of 80 yielded a macrocyclic analogue
containing two triazoles, eOC148 (81) that was synthesised
using a double copper-catalysed azide-alkyne cycloaddition
reaction. 81 was screened for activity against TAM family
members and RTKs FTL3 and RET based on the profile of 80.
While the screen showed macrocycle 81 was a moderate
inhibitor of AXL (IC50 = 13 μM), it did not inhibit the other
members of the TAM family or RET and had over 4-fold
selectivity over FTL3, a significant shift from 80.
Furthermore, 81 displayed potent antiproliferative activity
against MV4-11 cells, a myeloid leukaemia cell line
dependent on AXL for survival.132
VEGFR
Vascular endothelial growth factor receptor (VEGFR) is a family
of three transmembrane receptor tyrosine kinases that bind
growth factors extracellularly, which triggers homodimerization,
cross-phosphorylation of their intracellular kinase domains and
subsequent phosphorylation of multiple substrates.133 VEGFR
plays a key role in angiogenesis, the formation of new blood
vessels, as well as controlling immune cells present in the
microenvironment. Tumours initiate the process of
angiogenesis through VEGFs to provide them with nutrients,
allowing them to grow.134 Inhibition of these receptors has been
used to starve tumour environments of nutrients and potentially
limit their growth. Sorafenib (51) was the first VEGFR inhibitor
approved by the FDA for use in renal cell carcinoma. 51 is a
multi-kinase inhibitor, and has numerous other targets, a
common characteristic of VEGFR inhibitors due to its homology
of the ATP-site with other kinases. Further multi-kinase
inhibitors for VEGFR have also been approved and developed
for the treatment of cancer, including sunitinib, pazopanib,
vandetanib and cabozantinib (20).135
Pyrazolo[3,4-d]pyrimidines have been designed to inhibit
this VEGFR2, based on the different binding modes of
sorafenib (51) and linifanib, which binds to the ATP pocket
Fig. 19 Development of kinase inhibitors for AXL kinase. Lead
compound 80 (eSM119) was optimised for AXL-selectivity through a
strategy of macrocyclization to give 81 (eOC148).
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or to an allosteric pocket of VEGFR, respectively. Maintaining
the urea linked aryl-binder of the allosteric site, Kassab et al.
replaced the fused ring ATP-binder with a pyrazolo[3,4-d]
pyrimidine and designed 16 compounds primarily featuring
variations at the distal urea linked phenyl ring and minor
modifications to the N1-phenyl ring. The compounds were
evaluated in a panel of 60 tumour cell lines. Several
compounds showed broad anticancer activity, and the four
lead molecules (82–85, Fig. 20) were evaluated for their
VEGFR inhibition, demonstrating submicromolar IC50 values.
84, the most potent hit (IC50 = 220 nM), displayed
comparable inhibitory effects of VEGFR than 51.136
Conclusion and future directions
As shown in this review, the pyrazolo[3,4-d]pyrimidine scaffold
is a powerful starting point in medicinal chemistry programmes
due to facile derivatisation with a wide range of different groups
and functionalities. The independent or combined modification
of the moieties at the N1-, C3-, C4- and C6-positions have been
the focus of much research to modulate the kinase selectivity of
this privileged scaffold to specific or multiple targets. Its
bioisosterism with adenine, which confers the ability to bind to
the hinge region of the ATP site of many kinases even more
potently than adenine, makes this scaffold highly applicable in
the development of new kinase inhibitors. The exploitation of
this scaffold has been particularly fruitful for the development
of kinase inhibitors for the treatment of cancer. The fact that
one pyrazolo[3,4-d]pyrimidine, the BTK inhibitor ibrutinib (7th
best-selling cancer drug of 2018), has been approved to treat
B-cell cancers and several more inhibitors targeting different
kinases are in advanced clinical trials, demonstrate both the
therapeutic potential and versatility of this scaffold.137 In the
coming years, it is highly likely that further pyrazolo[3,4-d]
pyrimidines will be approved for the treatment of cancer
patients, especially for indications where there is limited or no
targeted therapies available. And given the broad bioactive
chemical space around this core yet to be uncovered, there is
little doubt that medicinal chemists will continue investing
efforts to thoroughly explore the possibilities that the
pyrazolo[3,4-d]pyrimidine scaffold are yet to offer.
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